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Abstract
Background: On its physiological cellular context, PTTG1 controls sister chromatid segregation
during mitosis. Within its crosstalk to the cellular arrest machinery, relies a checkpoint of integrity
for which gained the over name of securin. PTTG1 was found to promote malignant transformation
in 3T3 fibroblasts, and further found to be overexpressed in different tumor types. More recently,
PTTG1 has been also related to different processes such as DNA repair and found to trans-activate
different cellular pathways involving c-myc, bax or p53, among others. PTTG1 over-expression has
been correlated to a worse prognosis in thyroid, lung, colorectal cancer patients, and it can not be
excluded that this effect may also occur in other tumor types. Despite the clinical relevance and
the increasing molecular characterization of PTTG1, the reason for its up-regulation remains
unclear.
Method: We analysed PTTG1 differential expression in PC-3, DU-145 and LNCaP tumor cell
lines, cultured in the presence of the methyl-transferase inhibitor 5-Aza-2'-deoxycytidine. We also
tested whether the CpG island mapping PTTG1  proximal promoter evidenced a differential
methylation pattern in differentiated thyroid cancer biopsies concordant to their PTTG1
immunohistochemistry status. Finally, we performed whole-genome LOH studies using Affymetix
50 K microarray technology and FRET analysis to search for allelic imbalances comprising the
PTTG1 locus.
Conclusion: Our data suggest that neither methylation alterations nor LOH are involved in
PTTG1 over-expression. These data, together with those previously reported, point towards a
post-transcriptional level of missregulation associated to PTTG1 over-expression.
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Background
Human pituitary tumor-transforming protein (PTTG1) is
a 22-kDa protein proven to be tumorigenic in NIH3T3
fibroblasts [1] and further abundantly expressed in many
tumors. Under physiological conditions, PTTG1 expres-
sion is found to be regulated through the cell cycle, with a
peak at G2/M phase. PTTG1 primary function is related to
the control of sister chromatid separation to the opposite
spindle poles. According to this activity, genomic imbal-
ance as a result of chromosome missegregation is a ration-
ale for the oncogenic potential of upregulated PTTG1
expression. In fact, PTTG1 over-expression has been asso-
ciated with aneuploidy generation, what correlates with a
differentiated prognosis in multiple tumor types [2,3]. In
addition, PTTG1 and Fibroblast Growth Factor (FGF)
together form a positive feedback loop and stimulate
tumor angiogenesis [4,5]. Besides, PTTG1 may play a role
in double strand break reparation trough Ku-70 and regu-
lating cell proliferation and apoptosis transactivating c-
myc and bax [6-8]. Thus, there may be several possible
mechanisms for PTTG1 tumorigenesis [8].
From the pathological point of view, PTTG1 has been
found to be expressed at high levels in human pituitary
adenomas and other malignant tumors including breast,
lung, prostate, ovary and thyroid cancer, as well as in hae-
matopoietic neoplasias [9-15]. PTTG1 expression has
been correlated with lymph node invasion in colorectal
cancer and was proposed as an independent prognostic
molecular biomarker [16]. Moreover, increased PTTG1
expression levels and early tumor recurrence has been
found in different cancer series [11,17]. Finally, we have
recently reported that PTTG1 is highly expressed in two
thirds (65%) of the differentiated thyroid cancers of Span-
ish origin, and was shown to be an independent prognos-
tic factor for persistent disease among DTC patients [15].
Despite the large amount of data available, the molecular
mechanisms underlying PTTG1 over-expression have not
been clarified so far. In a previous work, Kanakis and cow-
orkers performed a sequencing scan in sixteen tumor
biopsies from pituitary adenoma patients, searching for
small deletion/insertion within those regions previously
identified to be controlling PTTG1 expression [18]. In
their study they conclude that promoter mutations do not
play a mayor role for the enhanced PTTG1 transcription
and suggested that promoter hypomethylation may be
responsible for PTTG1 over-expression.
It has been proposed that demethylation along the
genome largely affects the intergenic and intronic regions
of DNA, and it is believed to result in chromosomal insta-
bility and increased mutation events [19]. Under this
hypothesis, a CpG island identified close to the core
PTTG1 promoter may display a differential methylation
pattern in normal tissues when compared to their corre-
sponding tumors, and be also different between those
tumors with different PTTG1 expression levels. On the
other hand, other structural events such as gene amplifica-
tion could also explain the different over-expression levels
present in both tumor biopsies and tumor cell lines. Here,
we first investigate whether epigenetic and structural alter-
ations may explain PTTG1 upregulation in both tumor
cell lines and thyroid cancer biopsies. We have studied the
methylation status in a CpG island characterized in the
proximal promoter region of PTTG1, using methylation-
specific PCRs (MSPs). In addition, to test the presence of
a putative epigenetic control over PTTG1 expression we
performed PTTG1 expression analysis in three tumor cell
lines with different basal expression levels. We also evalu-
ated the possibility that loss of heterozygosity (LOH)
events involving the PTTG1 locus could also explain the
higher amount of protein present in different tumor biop-
sies and tumor cell lines.
Methods
Patients and controls
To isolate germline DNA, we obtained 5 ml of peripheral
blood. DNA extraction was performed automatically
according to standard procedures using Magnapure DNA
isolation system (Roche, Mannheim, Germany). Thyroid
biopsies were from 47 paraffin-embedded tissues (FPET)
of unrelated individuals with differentiated thyroid carci-
noma (DTC) and matched adjacent unaffected tissues
from the same individual. DNA extraction from FPET was
performed as previously described [20]. DNA samples
from 185 controls from Spanish population were
obtained from a previous work [21]. Institutional and eth-
ical review board from the referral centres approved the
consecution of this project
Immunohistochemical analysis of PTTG1
Immunohistochemistry was performed as previously
described [15]. Paraffin tissue sections (5 µm thick) were
dewaxed in xylene and rehydrated in a series of graded
alcohols. Sections were immersed in 3% H2O2 aqueous
solution for 30 min to quench endogenous peroxidase
activity, and then covered with 10% normal serum in Tris-
buffered saline to block nonspecific binding sites. A rabbit
polyclonal anti-PTTG1 antibody was available for this
study. Specificity control experiments for this antibody
have been described previously [13,22]. Sections were
incubated overnight with a 1:500 dilution of primary anti-
PTTG1 antibody. After several washes in Tris buffer, per-
oxidase-labeled secondary antibodies and 3,3'-diami-
nobenzidine were applied to develop immunoreactivity,
according to manufacturer's protocol (EnVision; Dako,
Glostrup, Denmark). The slides were then counterstained
with hematoxylin and mounted in DPX (BDH Laborato-BMC Cancer 2008, 8:110 http://www.biomedcentral.com/1471-2407/8/110
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ries, Poole, UK). Sections in which primary antibody was
omitted were used as negative controls.
Methylation-specific PCR
Genomic sequence from PTTG1 was obtained from public
databases (see Availability and requirements section for
URL, Unigene Hs.350966) and was analyzed using the
freely available CpG Island Searcher (see Availability and
requirements section for URL) developed according to the
algorithms previously reported [23] and confirmed using
the sequence analysis tool from the European Bioinfor-
matic Institute (see Availability and requirements section
for URL). Genomic DNA from both tumor samples and
their corresponding healthy tissues were treated with
bisulfite sulfoxide for 6 h at 50°C and further purified
using Methyldetector Kit (Active Motif, Carlsbad, Califor-
nia, USA) according to manufacturer's instructions.
Cell cultures
Human prostate cancer cell lines PC-3, DU-145 and
LNCaP were obtained from the Cell Line Collection
(Interlab, Genoa, Italy) and routinely grown in RPMI
1640 supplemented with 10% heat-inactivated fetal
bovine serum, 100 U/ml penicillin, 100 µg/ml streptomy-
cin and 1 mM glutamine in a 37°C, humidified incubator
under 5% CO2. 5-Aza-2'-deoxycytidine (5-Aza) (Sigma,
St. Louis, Missouri, USA) was prepared in dimethyl sulfox-
ide (DMSO). 3 × 105 cells were plated in 25 cm2 culture
flasks and allowed to adhere for 24 h. Then the cultures
were treated either with 2 µM 5-Aza or DMSO for 78 h,
with a medium and drug change every 24 h. Cell cultures
were harvested by trypsinization.
Western blotting
Western blotting was performed essentially as previously
described [24]. Briefly, twenty micrograms of total pro-
tein, as determined by using BCA protein assay kit (Pierce,
Rockford, Illinois, USA), were separated by SDS-PAGE on
4–20% gradient polyacrylamide gels (Invitrogen,
Carlsbad, California, USA). Gels were electroblotted onto
nitrocellulose membranes (Amersham, Little Chalfont,
UK). Ponceau Red staining was used to confirm equal
loading. For immunodetection, blots were blocked in 1%
blocking reagent (Roche) in 0.05% Tween 20-TBS for 1 h
and incubated with primary antibody overnight at 4°C
diluted in blocking buffer. Blots were then washed in
0.05% Tween 20-TBS and incubated with either goat anti-
mouse (1:20,000; Amersham) or goat anti-rabbit
(1:20,000; Amersham) peroxidase-labeled antibodies in
blocking buffer for 1 h. Enhanced chemoluminescent sys-
tem was applied according to the manufacturer's protocol
(Amersham). Monoclonal anti-Caspase 7 antibody was
available from BD Biosciences (San Jose, California,
USA). Dilutions used in Western blots were anti-PTTG1
(1:1,000), anti-Caspase 7 (1:2,000) and β-tubulin
(1:500).
Reverse-transcription and quantitative PCR
Total RNA was extracted using the Purescript® RNA Isola-
tion Kit (Gentra, Minneapolis, USA) according to the
manufacturer's protocol. 0.5 µg of total RNA was sub-
jected to DNase I (Invitrogen) digestion and subsequently
processed to cDNA by reverse transcription with Tran-
scriptor First Strand cDNA Synthesis Kit (Roche) accord-
ing to the manufacturer's protocol. All PCR reactions were
performed in a 25 µl reaction volume on the SmartCycler
II Real-Time PCR Detection System (Cepheid, Sunnyvale,
California, USA) using the Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen) and 500 nM of each specific
primer. PCR efficiencies were calculated using a relative
standard curve derived from 10-fold dilution series of
pooled cDNA mixture (a 10-fold dilution series with four
measuring points). The levels of PTTG1 and the house-
keeping gene RPL13A in each sample were quantified by
measuring the Ct values in duplicate. These mean Ct val-
ues were transformed to quantities using the delta-Ct
method. The sample with the lowest value was assigned
the value 1. The quantity of PTTG1 transcript was divided
by the quantity of RPL13A to obtain a normalized value.
Affymetrix 50 K microarrays
Affymetrix (San Diego, California, USA) 50 K Xba I arrays
were performed according to manufacturer's instructions.
Briefly, 250 ng of high molecular weight genomic DNAs
were digested with Xba I for 2 h. Next, a double-stranded
DNA adaptor was added and ligated to cohesive Xba I
ends. Following, PCR was performed in order to reduce
DNA complexity, being amplified those segments below 5
Kb. PCR products were purified and digested using DNAse
I to generate fragments of aprox. 200 bp, that were subse-
quently biotinylated. Samples were hybridized at 48°C
for 16 h and washed and stained using Affymetrix fluidic
station 450. Microchips were scanned the same day using
an Affymetrix 7G GeneChip scanner and analysed using
CNAT 4.0 software.
Genotyping using fluorescence resonance energy transfer 
(FRET)
Two informative polymorphisms mapping PTTG1 gene
were selected from HapMap database (rs3811999, Minor
Alelle Frequency (MAF): 0.4 and rs4921281, MAF: 0.21).
Every PCR reaction was performed in a final volume of 20
µl, containing 25 ng of genomic DNA, and 1× buffer from
Light Cycler®  Molecular probe master mix (Roche), 5
pmol of each primer and 2 pmol of each genotyping
probe. PCRs were performed in a Light Cycler® 480. Prim-
ers and amplification conditions are described in table 1.
Upon amplification, a melting curve from 50°C to 80°C
was performed while recording the Cy5 fluorescence.BMC Cancer 2008, 8:110 http://www.biomedcentral.com/1471-2407/8/110
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Results
Epigenetic regulation of PTTG1 expression
Genomic DNA sequence from PTTG1  gene was down-
loaded from public databases available and subjected to
two different CpG island discovery softwares. Both pro-
grams identified a region mapping the 5' site of PTTG1,
from -56 to -712 (in relation to translation start site) with
a high probability of being subjected to epigenetic control
(Figure 1). In order to study a putative epigenetic control
over PTTG1 expression, PC-3, DU-145 and LNCaP cell
lines were selected as in vivo models. These cell lines have
been utilized for PTTG1 expression control analysis since
they exhibit different PTTG1 expression levels under nor-
mal culture conditions (Figure 2A). Cells were cultured
either in the presence or absence of 2 µM 5-Aza, which is
known to inhibit the methyl-transferase complex, causing
genome-wide demethylation. After 78 h incubation in the
presence of the drug, cells were harvested and total pro-
tein was extracted and normalized. Samples were sub-
jected to SDS-PAGE and western blot, using anti-β-
tubulin as additional loading control. As positive induc-
tion control we measured CASP7 expression, which has
been reported to be epigenetically silenced under normal
culture conditions. As expected, we could observe a clear
up-regulation of CASP7 in those samples treated with 5-
Aza (+17%, +31% and +36% for PC3, DU-145 and
LNCaP, respectively). On the contrary, no up-regulation
was detected for PTTG1 expression in any of the three cell
lines under study (Figure 2A). In fact, PTTG1 expression
exhibited a slight inhibition upon treatment. This was
Table 1: Primers and amplification conditions.
Primer Sequence (5'-3') Amplicon Amplification conditions
PTTG MF1 TTTCGGATTGTTAATTGGATTAAC 168 bp 1. [95°C for 7'] 2. [95°C for 0'', 60°C for 20'', 72°C for 
25 '']x45 3. Melting curve
PTTG MR1 AAAAACAAAAACTAAACAACGAA 2. [95°C for 0'', 60°C for 20'', 72°C for 25 ''] × 45
PTTG UF1 TTGGATTGTTAATTGGATTAATGG 166 bp 3. Melting curve
PTTG UR1 AAAAACAAAAACTAAACAACAAA
PTTG MF2 GTTTTATTTGGTGATTACGTTTACG 123 bp 1. [95°C for 7']
PTTG MR2 ACCGCATTCATCTAAAACCG 2. [95°C for 0'', 60°C for 20'', 72°C for 25 ''] × 45
PTTG UF2 TTTTATTTGGTGATTATGTTTATGG 125 bp 3. Melting curve
PTTG UR2 ACAACCACATTCATCTAAAACCAC
PTTG-1F AAAGTAGCTACCATTCCTGC 124 bp 1. [95°C for 7'] 2. [95°C for 30'', 60°C for 30'', 72°C for 
30 '']x45 3. [72°C for 3']
PTTG-1R TGCCCTGTAAAAGCAAAAT 2. [95°C for 30'', 60°C for 30'', 72°C for 30 ''] × 45
PTTG-1 Anc FL-AATAGCCCAACATAATAGAATCTATTTT-Ph 3. [72°C for 3']
PTTG-1 Sen GCTACCATTCCTGCCTTAATA-Cy5
PTTG-3F TGCTGACAGGTGCTGGTACT 128 bp 1. [95°C for 7'] 2. [95°C for 30'', 60°C for 30'', 72°C for 
30 '']x45 3. [72°C for 3']
PTTG-3R AAGAAGCCATAATCCTTAGTTTTCA 2. [95°C for 30'', 60°C for 30'', 72°C for 30 ''] × 45
PTTG-3 Anc FL-TTTGAGTCATGCTACTCGAATTACAT-Ph 3. [72°C for 3']
PTTG-3 Sen GGTACTTAAATTTCCGATTTTAAC-Cy5
p16 Forward outer GTAGGTGGGGAGGAGTTTAGTT 283 bp 1. [94°C for 3']
p16 Reverse outer TCTAATAACCAACCAACCCCTCC 2. [94°C for 30'', 50°C for 30'', 72°C for 30''] × 20
3.[72°C for 4']
p16 Forward inner GGGGGAGATTTAATTTGG 190 bp 1. [94°C for 3'] 2. [94°C for 30'', 50°C for 30'', 72°C for 
30''] × 30 3. [72°C for 4']
p16 Reverse inner CCCTCCTCTTTCTTCCTC 2. [94°C for 30'', 50°C for 30'', 72°C for 30''] × 30
3. [72°C for 4']
qPCR PTTG Fw AGGCACCCGTGTGGTTGCT 126 bp 1. [50°C for 2']
qPCR PTTG Rev TAAGGCTGGTGGGGCATC 2. [95°C for 2']
qPCR RPL13A Fw CCTGGAGGAGAAGAGGAAAGAGA 125 bp 3. [95°C for 5'', 60°C for 30''] × 40
qPCR RPL13A Rev TTGAGGACCTCTGTGTATTTGTCAA 4. Melting curveBMC Cancer 2008, 8:110 http://www.biomedcentral.com/1471-2407/8/110
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especially evident for PC-3 and LNCaP, which exhibited
12% PTTG1 downregulation. To confirm these data, total
RNA was extracted from the different cell lines under the
culture conditions previously mentioned and subjected to
RT-qPCR analysis. According to these assays, PTTG1
mRNA expression levels were lowered in all cases 3–5%
upon treatment, giving additional support to the results
previously obtained (data not shown).
Methylation-specific PCR analysis of DTC biopsies and 
tumor cell lines
As described above, we identified a 650 bp region with
high probability of being subjected to epigenetic control.
Next, two sets of primers were design to test and quantify
the presence of unmethylated cytosines residues among
our samples. With this approach, the same converted
DNA sample is subjected to two independent PCRs; the
Structural search for CpG islands within PTTG1 Figure 1
Structural search for CpG islands within PTTG1. Design of the primer sets for MSPs. The upper graph represents the 
GC content expressed as observed/expected along the entire PTTG1 genomic sequence according to the CpG Island Searcher. 
The middle graph represents the region identified as a putatively functional CpG island, mapping the proximal promoter. This 
region was subjected to further analysis to refine the critical region and design the necessary MSP primer sets. In the lower 
graph the critical region is designated as a shadow below the CG percentage. Vertical bars represent each CG pair. Squares 
represent the different primer sets, designed to amplify if methylated before treatment (black) or unmethylated (grey)
+1 ATG BMC Cancer 2008, 8:110 http://www.biomedcentral.com/1471-2407/8/110
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first, using two primer pairs designed towards the
unmethylated cytosines, and two primer pairs designed
towards the methylated residues (Figure 1). Since bisulfite
treatment strongly degrades DNA, samples from both
PTTG1 positive and negative biopsies were examined for
degradation in low-melting agarose gels and purity
(OD260/OD280 ratio) prior to conversion treatment. Next,
DNA of three representative samples from each tumor
type were extracted together with DNA from its adjacent
healthy tissue to be taken as inner reference as well as
genomic DNAs from PC-3, DU-145 and LNCaP cells. All
samples (n = 15) were treated with sodium bisulfite as
stated in materials and methods, in order to convert
unmethylated cytosines to uracil residues. As positive con-
version control, all DNA samples were tested for amplifi-
cation using nested MSP designed for p16-ink according
to manufacturer's instructions and as previously stated
[25].
Upon full conversion was confirmed, converted DNA
samples were subjected to MSP analysis using both sets of
primers aforementioned. To determine the sensitivity of
MSPs, serial ratios of converted:untreated DNAs were per-
formed and subjected to real-time MSP to measure the
amplification crossing point [see Additional file 1].
According to MSP analysis, all tumor samples displayed
unmethylated CpG island regardless their PTTG1 status,
as well as their respective contra-lateral healthy tissue. PC-
3, DU-145 and LNCaP cell lines also exhibited unmethyl-
ated PTTG1 promoter despite their different expression
pattern (Figure 2B and 2C). Altogether, our data suggest
that PTTG1 expression levels do not correlate with CpG
methylation status.
Loss of heterozygosity studies within the PTTG1 locus
In order to test whether the different PTTG1 expression
levels could be explained by gene amplification, we sub-
jected PC-3, DU-145 and LNCaP cell lines and two con-
trol germline DNAs to Affymetrix 50 K Xba I array
analysis. This platform offers a quantitative mapping
analysis of the genome at a median intermaker distance of
16 Kb. Gene dosage and loss of heterozygosity were ana-
lysed using CNAT 4.0 software, and data from chromo-
some 5 was filtered and represented in figure 3. We
observed that several LOH regions (threshold ≥ 15) were
common to PC-3 and DU-145 cell lines, and others
restricted to each one. However, none of them involved
the region mapping PTTG1 gene.
Due to technical restrictions, the 50 K Xba I array can not
be used for paraffin embedded tissues-derived DNA anal-
ysis, and after a careful bioinformatic search, no suitable
microsatellite was present in our region of interest to be
analyzed to detect putative LOH regions. Thus, we
selected from HapMap database two highly informative
polymorphisms mapping PTTG1  gene (rs3811999 and
Methylation analysis of PTTG1 expression Figure 2
Methylation analysis of PTTG1 expression. A) Western blotting analysis of each cell line cultured in the presence or 
absence of 5-Aza. B) MSP analysis of tumor cell lines. Converted DNA is subjected to three different PCR reactions. For each 
primer set, two primer pairs are used to determine if the PTTG1 locus is methylated (M) or unmethylated (U). Bisulfite conver-
sion control is performed by amplifying p16-Ink locus. C) MSP analysis of tumor samples with low (TS1-3) or high PTTG1 
expression levels (TS4-6).
DU-145  PC-3  LNCaP 
p16-Ink
-      + -      + -       + Bisulfite
M    U M    U M    U 
DU-145  PC-3  LNCaP 
PTTG1 
Set 2 
Set 1
B) 
DU-145 PC-3 LNCaP
-       + -       + -       + 5-Aza
CASP7
A)
β-Tubulin
PTTG1 PTTG1 
 Set 2 
Set 1
C) 
M  U M  U M  U  M  U M  U M  U 
TS1  TS2  TS3  TS4  TS5  TS6 
P16-Ink
-    +   -    + -   +  -    + -    + -    +  Bisulfite 
TS1  TS2  TS3  TS4  TS5  TS6 BMC Cancer 2008, 8:110 http://www.biomedcentral.com/1471-2407/8/110
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rs4921281) and genotyped them in a series from general
Spanish population (n = 186). Both minor allele frequen-
cies did not significantly differ from the ones described
from the public database (0.37 vs 0.4 for rs3811999 and
0.16 vs 0.21 for and rs4921281). Thus, empirical inform-
ativeness for each SNP was 0.48 and 0.27 respectively. Fol-
lowing, we genotyped both the tumor samples (n = 47)
and their corresponding contra-lateral healthy tissues.
Perfect concordance was obtained between those geno-
types obtained using tumor and healthy samples, giving
additional support to Affymetrix results and supporting
the theory that no LOH event had occurred involving
PTTG1 gene.
Discussion
Growing evidences arise from the literature linking PTTG1
over-expression to both tumor growth and a worse prog-
nosis among independent patient series. According to a
leading theory, PTTG1 over-expression may generate a
chromosomal instability phenotype associated to a subset
of genomic rearrangements leading to a worse prognosis.
In this context, different authors proposed PTTG1 as a
strong candidate for drug target design and thus, a deeper
knowledge of the mechanism underlying PTTG1 upregu-
lation in tumoral cells may contribute to the development
of effective therapeutic strategies.
In this study, we have tested whether structural DNA alter-
ations such as CpG methylation or LOH may explain
PTTG1 expression levels in both cell lines and DTC tumor
Genome-wide LOH scan using Affymetrix 50 K Xba I array Figure 3
Genome-wide LOH scan using Affymetrix 50 K Xba I array. Graphs represent the LOH likelihood (Y-axis) respect to 
the base-pair. Chromosomes are represented in the X-axis. As a reference, we used peripheral-blood derived DNA from a 
healthy control from Spanish population. In the lower graph, chromosome 5 is enlarged and the PTTG1 locus is marked.
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and healthy samples. Experiments using tumor cell lines
cultured in the presence or absence of 5-Aza reveal that
hypomethylation seems not to be involved in PTTG1
over-expression. On the contrary, our results may suggest
that genome-wide hypomethylation obtained using 5-Aza
treatment results in PTTG1 repression in three different
genetic backgrounds, altough the elucidation of this point
would require further investigation. According to our data
derived from the MSP analysis performed over the CpG
island mapping the PTTG1 close promoter analysed in
both DTC biopsies and cell lines, the CpG island mapping
PTTG1  close-promoter appears unmethylated in both
healthy tissues and tumor samples, regardless their PTTG1
expression status.
In addition, it seems that LOH phenomena may also not
be involved in PTTG1 over-expression, according to
Affymetrix results and those obtained from the genotyp-
ing experiments, where no allelic imbalance has been
observed. These data together with those previously
reported by Kanakis et al [18] suggest the presence of
other mechanism as a leading cause for PTTG1 over-
expression such as post-transcriptional missregulation,
leading to either a longer mRNA stabilization or increased
protein mean-live. However, we can not exclude the pos-
sibility that additional epigenetic alterations such as his-
tone acetylation or ubiquitylation may be playing
important roles in regulating PTTG1 expression levels.
To date, different PTTG1 transcriptional regulators have
been identified. Zhou et al showed that Sp1 binds
together with NF-Y to PTTG1 promoter sequence, and that
site-directed mutagenesis of the Sp1 consensus sequence
resulted in approximately 70% reduction of the transcrip-
tional activation of the promoter, whilst mutation of the
NF-Y binding site resulted in 25% reduction. Deletion of
both Sp1 and NF-Y sequences resulted in a 90% loss of
PTTG1 promoter activity [26]. Others have identified that
WldS might also be involved in PTTG1 expression control,
as well as beta-catenin [27,28]. Nevertheless, no conclu-
sive experiments have been reported to our knowledge
explaining the nature of PTTG1 over-expression in tumor
samples. On the other hand, if we focus on PTTG1 mRNA
stabilization or PTTG1 degradation pathways, results are
scarce. Recently, protein phosphatase 2A has been
involved in the stabilization and increased mean life of
PTTG1, suggesting that impaired degradation could be rel-
evant in the upregulation of PTTG1 [29]. However, further
investigation is needed to completely elucidate the under-
lying mechanism of PTTG1 upregulation in tumors.
Conclusion
To date, growing evidences are being reported pointing
towards a worse clinical outcome associated to PTTG1
expression. However, the mechanisms underlying such
deregulation remain unclear. We failed to correlate PTTG1
expression rates with a specific methylation pattern of the
CpG island mapping -56 to -712 of PTTG1  promoter.
Moreover, culture experiments corroborate these data and
suggest that genome-wide hypomethylation is not associ-
ated to PTTG1 over-expression. In addition, LOH studies
were also negative for the region mapping the PTTG1
locus, although positive for many others. In summary,
these data together with those previously reported suggest
that primary structural alterations of PTTG1 gene are not
major mechanisms involved in PTTG1 over-expression.
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